Skip to main content
PMC home page
The Journal of Experimental Medicine logoLink to The Journal of Experimental Medicine
. 1996 Sep 1;184(3):883–891. doi: 10.1084/jem.184.3.883

Selective neutralization of prostaglandin E2 blocks inflammation, hyperalgesia, and interleukin 6 production in vivo

PMCID: PMC2192784  PMID: 9064348

Abstract

The role of prostaglandin E2 (PGE2) in the development of inflammatory symptoms and cytokine production was evaluated in vivo using a neutralizing anti-PGE2 monoclonal antibody 2B5. In carrageenan-induced paw inflammation, pretreatment of rats with 2B5 substantially prevented the development of tissue edema and hyperalgesia in affected paws. The antibody was shown to bind the majority of PGE2 produced at the inflammatory site. In adjuvant-induced arthritis, the therapeutic administration of 2B5 to arthritic rats substantially reversed edema in affected paws. Anti-PGE2 treatment also reduced paw levels of IL-6 RNA and serum IL-6 protein without modifying tumor necrosis factor RNA levels in the same tissue. In each model, the antiinflammatory efficacy of 2B5 was indistinguishable from that of the nonsteroidal antiinflammatory drug indomethacin, which blocked the production of all PGs. These results indicate that PGE2 plays a major role in tissue edema, hyperalgesia, and IL-6 production at sites of inflammation, and they suggest that selective pharmacologic modulation of PGE2 synthesis or activity may provide a useful means of mitigating the symptoms of inflammatory disease.

Full Text

The Full Text of this article is available as a PDF (986.7 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Anderson G. D., Hauser S. D., McGarity K. L., Bremer M. E., Isakson P. C., Gregory S. A. Selective inhibition of cyclooxygenase (COX)-2 reverses inflammation and expression of COX-2 and interleukin 6 in rat adjuvant arthritis. J Clin Invest. 1996 Jun 1;97(11):2672–2679. doi: 10.1172/JCI118717. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Bailly S., Ferrua B., Fay M., Gougerot-Pocidalo M. A. Differential regulation of IL 6, IL 1 A, IL 1 beta and TNF alpha production in LPS-stimulated human monocytes: role of cyclic AMP. Cytokine. 1990 May;2(3):205–210. doi: 10.1016/1043-4666(90)90017-n. [DOI] [PubMed] [Google Scholar]
  3. Coleman R. A., Smith W. L., Narumiya S. International Union of Pharmacology classification of prostanoid receptors: properties, distribution, and structure of the receptors and their subtypes. Pharmacol Rev. 1994 Jun;46(2):205–229. [PubMed] [Google Scholar]
  4. Davies P., Bailey P. J., Goldenberg M. M., Ford-Hutchinson A. W. The role of arachidonic acid oxygenation products in pain and inflammation. Annu Rev Immunol. 1984;2:335–357. doi: 10.1146/annurev.iy.02.040184.002003. [DOI] [PubMed] [Google Scholar]
  5. Dendorfer U., Oettgen P., Libermann T. A. Multiple regulatory elements in the interleukin-6 gene mediate induction by prostaglandins, cyclic AMP, and lipopolysaccharide. Mol Cell Biol. 1994 Jul;14(7):4443–4454. doi: 10.1128/mcb.14.7.4443. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Ferreira S. H., Nakamura M., de Abreu Castro M. S. The hyperalgesic effects of prostacyclin and prostaglandin E2. Prostaglandins. 1978 Jul;16(1):31–37. doi: 10.1016/0090-6980(78)90199-5. [DOI] [PubMed] [Google Scholar]
  7. Ferreira S. H. Prostaglandins, aspirin-like drugs and analgesia. Nat New Biol. 1972 Dec 13;240(102):200–203. doi: 10.1038/newbio240200a0. [DOI] [PubMed] [Google Scholar]
  8. Ferreri N. R., Sarr T., Askenase P. W., Ruddle N. H. Molecular regulation of tumor necrosis factor-alpha and lymphotoxin production in T cells. Inhibition by prostaglandin E2. J Biol Chem. 1992 May 5;267(13):9443–9449. [PubMed] [Google Scholar]
  9. Futaki N., Yoshikawa K., Hamasaka Y., Arai I., Higuchi S., Iizuka H., Otomo S. NS-398, a novel non-steroidal anti-inflammatory drug with potent analgesic and antipyretic effects, which causes minimal stomach lesions. Gen Pharmacol. 1993 Jan;24(1):105–110. doi: 10.1016/0306-3623(93)90018-s. [DOI] [PubMed] [Google Scholar]
  10. Goetzl E. J., An S., Smith W. L. Specificity of expression and effects of eicosanoid mediators in normal physiology and human diseases. FASEB J. 1995 Aug;9(11):1051–1058. doi: 10.1096/fasebj.9.11.7649404. [DOI] [PubMed] [Google Scholar]
  11. Griswold D. E., Hillegass L. M., Breton J. J., Esser K. M., Adams J. L. Differentiation in vivo of classical non-steroidal antiinflammatory drugs from cytokine suppressive antiinflammatory drugs and other pharmacological classes using mouse tumour necrosis factor alpha production. Drugs Exp Clin Res. 1993;19(6):243–248. [PubMed] [Google Scholar]
  12. Hallinan E. A., Hagen T. J., Husa R. K., Tsymbalov S., Rao S. N., vanHoeck J. P., Rafferty M. F., Stapelfeld A., Savage M. A., Reichman M. N-substituted dibenzoxazepines as analgesic PGE2 antagonists. J Med Chem. 1993 Oct 29;36(22):3293–3299. doi: 10.1021/jm00074a010. [DOI] [PubMed] [Google Scholar]
  13. Hargreaves K., Dubner R., Brown F., Flores C., Joris J. A new and sensitive method for measuring thermal nociception in cutaneous hyperalgesia. Pain. 1988 Jan;32(1):77–88. doi: 10.1016/0304-3959(88)90026-7. [DOI] [PubMed] [Google Scholar]
  14. Higgs E. A., Moncada S., Vane J. R. Inflammatory effects of prostacyclin (PGI2) and 6-oxo-PGF1alpha in the rat paw. Prostaglandins. 1978 Aug;16(2):153–162. doi: 10.1016/0090-6980(78)90018-7. [DOI] [PubMed] [Google Scholar]
  15. Higgs G. A., Moncada S., Salmon J. A., Seager K. The source of thromboxane and prostaglandins in experimental inflammation. Br J Pharmacol. 1983 Aug;79(4):863–868. doi: 10.1111/j.1476-5381.1983.tb10530.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Kunkel S. L., Spengler M., May M. A., Spengler R., Larrick J., Remick D. Prostaglandin E2 regulates macrophage-derived tumor necrosis factor gene expression. J Biol Chem. 1988 Apr 15;263(11):5380–5384. [PubMed] [Google Scholar]
  17. Masferrer J. L., Zweifel B. S., Manning P. T., Hauser S. D., Leahy K. M., Smith W. G., Isakson P. C., Seibert K. Selective inhibition of inducible cyclooxygenase 2 in vivo is antiinflammatory and nonulcerogenic. Proc Natl Acad Sci U S A. 1994 Apr 12;91(8):3228–3232. doi: 10.1073/pnas.91.8.3228. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Mnich S. J., Veenhuizen A. W., Monahan J. B., Sheehan K. C., Lynch K. R., Isakson P. C., Portanova J. P. Characterization of a monoclonal antibody that neutralizes the activity of prostaglandin E2. J Immunol. 1995 Nov 1;155(9):4437–4444. [PubMed] [Google Scholar]
  19. Moncada S., Ferreira S. H., Vane J. R. Prostaglandins, aspirin-like drugs and the oedema of inflammation. Nature. 1973 Nov 23;246(5430):217–219. doi: 10.1038/246217a0. [DOI] [PubMed] [Google Scholar]
  20. Moncada S., Palmer R. M., Higgs E. A. Nitric oxide: physiology, pathophysiology, and pharmacology. Pharmacol Rev. 1991 Jun;43(2):109–142. [PubMed] [Google Scholar]
  21. Morita I., Schindler M., Regier M. K., Otto J. C., Hori T., DeWitt D. L., Smith W. L. Different intracellular locations for prostaglandin endoperoxide H synthase-1 and -2. J Biol Chem. 1995 May 5;270(18):10902–10908. doi: 10.1074/jbc.270.18.10902. [DOI] [PubMed] [Google Scholar]
  22. Needleman P., Turk J., Jakschik B. A., Morrison A. R., Lefkowith J. B. Arachidonic acid metabolism. Annu Rev Biochem. 1986;55:69–102. doi: 10.1146/annurev.bi.55.070186.000441. [DOI] [PubMed] [Google Scholar]
  23. O'Sullivan M. G., Chilton F. H., Huggins E. M., Jr, McCall C. E. Lipopolysaccharide priming of alveolar macrophages for enhanced synthesis of prostanoids involves induction of a novel prostaglandin H synthase. J Biol Chem. 1992 Jul 25;267(21):14547–14550. [PubMed] [Google Scholar]
  24. Otto J. C., Smith W. L. The orientation of prostaglandin endoperoxide synthases-1 and -2 in the endoplasmic reticulum. J Biol Chem. 1994 Aug 5;269(31):19868–19875. [PubMed] [Google Scholar]
  25. Peters-Golden M., McNish R. W. Redistribution of 5-lipoxygenase and cytosolic phospholipase A2 to the nuclear fraction upon macrophage activation. Biochem Biophys Res Commun. 1993 Oct 15;196(1):147–153. doi: 10.1006/bbrc.1993.2227. [DOI] [PubMed] [Google Scholar]
  26. Pettipher E. R., Wimberly D. J. Cyclooxygenase inhibitors enhance tumour necrosis factor production and mortality in murine endotoxic shock. Cytokine. 1994 Sep;6(5):500–503. doi: 10.1016/1043-4666(94)90077-9. [DOI] [PubMed] [Google Scholar]
  27. Raz A., Wyche A., Siegel N., Needleman P. Regulation of fibroblast cyclooxygenase synthesis by interleukin-1. J Biol Chem. 1988 Feb 25;263(6):3022–3028. [PubMed] [Google Scholar]
  28. Regier M. K., Otto J. C., DeWitt D. L., Smith W. L. Localization of prostaglandin endoperoxide synthase-1 to the endoplasmic reticulum and nuclear envelope is independent of its C-terminal tetrapeptide-PTEL. Arch Biochem Biophys. 1995 Mar 10;317(2):457–463. doi: 10.1006/abbi.1995.1188. [DOI] [PubMed] [Google Scholar]
  29. Seibert K., Zhang Y., Leahy K., Hauser S., Masferrer J., Perkins W., Lee L., Isakson P. Pharmacological and biochemical demonstration of the role of cyclooxygenase 2 in inflammation and pain. Proc Natl Acad Sci U S A. 1994 Dec 6;91(25):12013–12017. doi: 10.1073/pnas.91.25.12013. [DOI] [PMC free article] [PubMed] [Google Scholar]
  30. Smith J. B., Ogletree M. L., Lefer A. M., Nicolaou J. C. Antibodies which antagonise the effects of prostacyclin. Nature. 1978 Jul 6;274(5666):64–65. doi: 10.1038/274064a0. [DOI] [PubMed] [Google Scholar]
  31. Smith W. L. The eicosanoids and their biochemical mechanisms of action. Biochem J. 1989 Apr 15;259(2):315–324. doi: 10.1042/bj2590315. [DOI] [PMC free article] [PubMed] [Google Scholar]
  32. WINTER C. A., RISLEY E. A., NUSS G. W. Carrageenin-induced edema in hind paw of the rat as an assay for antiiflammatory drugs. Proc Soc Exp Biol Med. 1962 Dec;111:544–547. doi: 10.3181/00379727-111-27849. [DOI] [PubMed] [Google Scholar]
  33. Williams T. J., Morley J. Prostaglandins as potentiators of increased vascular permeability in inflammation. Nature. 1973 Nov 23;246(5430):215–217. doi: 10.1038/246215a0. [DOI] [PubMed] [Google Scholar]
  34. Williams T. J. Prostaglandin E2, prostaglandin I2 and the vascular changes of inflammation. Br J Pharmacol. 1979 Mar;65(3):517–524. doi: 10.1111/j.1476-5381.1979.tb07860.x. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from The Journal of Experimental Medicine are provided here courtesy of The Rockefeller University Press

RESOURCES